CancerVax Achieves Major Milestone in Activating Human Killer T-Cells Against Cancer
In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.
CancerVax Named a Top Preclinical Biotech Company of 2026 by Life Sciences Review
Independent industry recognition highlights the Company’s revolutionary immunotherapy platform and growing momentum in precision cancer treatment.
CancerVax Develops Novel Smart mRNA to Harness Pre-Existing Immunity in 99% of World Population
Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity.
CancerVax Successfully Demonstrates Full Nanoparticle Delivery in Mouse Study
First biodistribution study of the Company’s complete cancer targeting nanoparticle avoided many healthy organs.
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.
CancerVax Reports Nanoparticle Component Success in Preparation for Animal Studies
In-vitro studies confirmed strong uptake of cell-targeting nanoparticles by cancer cells and strong activation of Smart mRNAs inside cancer cells
CancerVax Precision Therapy Successfully Avoids Healthy Liver Cells
In-vitro studies confirm that the Company’s novel Smart mRNA could drastically reduce off-target liver toxicity, a major issue affecting many cancer drugs
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform
CancerVax Achieves Major Milestones and Files Foundational Patent Application
The Company filed a substantial non-provisional PCT patent application seeking worldwide protection for its novel cancer treatment platform
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
Using AI machine learning, the Company discovers distinct biomarkers for detecting certain rare liver cancers that have stem cell characteristics and will include them as additional indications in its preclinical program
CancerVax Scientists Featured on Cytiva’s “Discovery Matters” Podcast Discussing Universal Cancer Vaccine Platform
Dr. George Katibah and Dr. Adam Grant describe the features and progress of the Company’s revolutionary technology
CancerVax Passes First Test with Flying Colors
Recent in-vitro lab results confirm that the Company’s Smart mRNA can be used as a potential on/off switch for selectively detecting cancer cells
